Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) EPS (Weighted Average and Diluted) (2016 - 2025)

IGC Pharma (IGC) has disclosed EPS (Weighted Average and Diluted) for 11 consecutive years, with -$0.02 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed 0.0% to -$0.02 in Q3 2025 year-over-year; TTM through Sep 2025 was -$0.08, a 57.89% increase, with the full-year FY2025 number at -$0.09, up 59.09% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.02 for Q3 2025 at IGC Pharma, roughly flat from -$0.02 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.02 in Q1 2025 to a low of -$0.09 in Q4 2023.
  • A 3-year average of -$0.04 and a median of -$0.02 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): soared 77.78% in 2024, then changed 0.0% in 2025.
  • IGC Pharma's EPS (Weighted Average and Diluted) stood at -$0.09 in 2023, then surged by 77.78% to -$0.02 in 2024, then changed by 0.0% to -$0.02 in 2025.
  • Per Business Quant, the three most recent readings for IGC's EPS (Weighted Average and Diluted) are -$0.02 (Q3 2025), -$0.02 (Q2 2025), and -$0.02 (Q1 2025).